Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
102
resultados
Última actualización
26/04/2026 [07:19:00]
Resumen de: WO2026084839A1
The present disclosure provides a Salmonella therapeutic delivery system having a modified surface for evading the host immune system, and methods of use thereof.
Resumen de: WO2026085295A1
Provided herein are kits, compositions, systems, and methods for treating a subject with a tumor with kynurenine responsive and degrading bacteria (e.g., such that the bacteria reduces or eliminates the tumor). In certain embodiments, the kynurenine responsive bacteria comprise one or more nucleic acid sequences encoding: i) a kynurenine transcriptional regulator protein, ii) a kynurenine transporter protein, iii) a kynureninase (KynU) protein, and iv) at least one protein important or essential for growth of the bacteria expression of which is linked to a kynurenine responsive promoter (e.g., where the corresponding gene(s) has been deactivated or knocked out in the genome of the bacteria).
Resumen de: CN121896139A
本发明属于兽医生物制品领域，具体涉及一株驴源马流产沙门菌spiC基因缺失株YZUSAL01ΔspiC及其构建方法和应用。本发明的基因缺失株已保藏于中国典型培养物保藏中心，保藏编号为CCTCC NO:M 20252392。该缺失株是利用λ‑Red同源重组技术，将马流产沙门菌的spiC基因敲除后获得的。本发明制备的基因缺失株毒力显著下降，具有良好的安全性。攻毒保护试验表明该菌株对小鼠的攻毒免疫保护效果良好，可诱导高效的体液免疫。本发明为预防马流产沙门菌感染提供了安全、保护效力高的减毒活疫苗奠定基础。
Resumen de: GB2701058A
A method for quantification of O-specific polysaccharide (OSP) content in a sample, the method comprises: (a) adding a chromogen to the sample to obtain a mixture, where the sample is optionally diluted with a buffer prior to the addition of the chromogen; (b) mixing an acid to the mixture obtain a solution; (c) incubating the solution; (d) subjecting the incubated solution to a spectrophotometric assay or a colorimetric assay; and (e) quantifying the O-specific polysaccharide content in the sample using a mixed saccharide standard solution; where the mixed saccharide standard solution comprises at least two saccharides. The chromogen may be phenol, and the acid may be sulphuric acid. Preferably, the mixed saccharide standard solution comprises rhamnose, mannose, galactose, and paratose in a ratio of about 1:1:1:0.76:1. The method may be used in a method of quantifying the OSP of a conjugate vaccine formulation that induces an immune response against bacterial capsular polysaccharides, such as Typhoid Conjugate Vaccine - Salmonella paratyphi. no figure
Resumen de: WO2024254419A2
Salmonella typhimurium comprising a first heterologous nucleic acid encoding a first polypeptide that causes bacterial lysis, a second heterologous nucleic acid encoding a second polypeptide that causes vacuolar lysis, and a third heterologous nucleic acid encoding a virus.
Resumen de: CN121851118A
本发明属于生物技术与兽医药领域，公开了一种能穿透肠道屏障的耐药沙门氏菌抗菌肽及应用。该抗菌肽能够选择性穿透被感染的宿主细胞（如巨噬细胞、肠上皮细胞）并清除胞内寄生菌，且对宿主细胞无明显毒性。其在肠道局部具备良好的作用稳定性。将该抗菌肽添加于禽类饲料中，可极显著提高沙门氏菌感染禽类的存活率，并显著降低脏器带菌量，其效果显著优于传统抗生素添加剂。本发明提供了一种作用机制清晰、高效安全、不易诱导耐药、符合绿色无抗养殖要求的饲料添加剂新方案。
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: WO2024201502A1
Present invention provides fusion proteins with desired reduction in factor H binding, particularly the present invention provides optimized manufacturing process for fusion proteins and formulations comprising the fusion proteins. Present invention provides an efficient platform process for manufacturing an effective vaccine formulation against Neisseria meningitidis that meets multiple criteria including improved immunogenicity, safety, stability, and affordability.
Resumen de: WO2026076273A1
Described herein are synthetic glycopolypeptides that contain sugars identified as active in mucin. These compounds reduce the virulence of high-priority opportunistic pathogens, including, but not limited to, Salmonella enterica subsp. enterica serovar Typhimurium, Candida albicans, and Gardnerella vaginalis, without reducing the viability of beneficial Lactobacillus crispatus. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: WO2025042889A1
The present disclosure provides formulations, kits, and vaccines directed to immunization of animals against Salmonella. Methods of usng the formulations, kits, and vaccines for protection of avians against one or more species of Salmonella are also provided.
Resumen de: AU2026201838A1
Provided are novel methods for screening and testing for pathogens in food, water, and bodily fluids using methods that are faster to complete than conventional methods of culturing and plating that require lengthy times in properly equipped labs. The invention utilizes specific, rapid and sensitive optical detection to capture small concentrations of the 5 target bacteria and render them amenable for detection with various specific synthesis binding agents approaches. The technique merges capture and detection steps with quantification unit suitable to provide results in a relatively shorter time current detection methods. methods. ar a r m e t h o d s
Resumen de: AU2026201863A1
The present invention features compositions comprising an anti-amyloid antibody and methods of treating microbial infection and treating or preventing microbial biofilms using the composition. 5 ar a r
Resumen de: US20260092082A1
An antimicrobial peptide having an amino acid sequence selected from SEQ ID NOs: 2-12 is provided. The antimicrobial peptide has antimicrobial activity against Gram-negative bacteria, Campylobacter jejuni, Escherichia coli, Salmonella enterica subsp. enterica serovar typhimurium, Salmonella enterica subsp. enterica serovar choleraesuis, Klebsiella pneumonica, and/or Enterobacter cloacae. A composition, pharmaceutical composition, food additive, cosmetic composition, or hygine product having an antimicrobial peptide including an amino acid sequence selected from SEQ ID NOs: 2-12 is also provided. A method of treating an infectious disease caused by bacteria including a step of administering a pharmaceutical composition having the antimicrobial peptide as an active ingredient is also provided.
Resumen de: WO2025037284A2
A vaccine and methods of treatment thereof, wherein the vaccine comprises a recombinant Gram-negative bacteria genetically modified to express a first antigen fusion peptide comprising a neoantigen or series thereof, said neoantigen or series thereof associated with a first secretion signal from a double membrane-spanning secretion system and a second antigen fusion peptide comprising a homologous neoantigen or series thereof, associated with a second secretion signal from an outer membrane-spanning secretion system. The Gram-negative bacteria may be further modified for quadmodal transport. Specifically, the fusion peptides include signal peptides are each associated with a Type III (T3SS) and a Type V (T5SS) secretion system.
Resumen de: NZ757251A
The present invention refers to pharmaceutical products comprising immunogenic compositions for modulating the immune system, which therapeutically effective amount of a Immmological Response Shifter (IRS) comprising two or more immunoactive antigenic agents presenting pathogen-associated molecular patterns (PAMPS) and/or danger associated molecular patterns (DAMPS) and/or Stress Response Signals (SRS) in association with an antibiotic and one or more physiologically acceptable carriers, excipients, diluents or solvents. In other embodiments, the present invention refers to methods to treat severe bacterial infections, sepsis and modulating the immune system.
Resumen de: NZ752371A
This disclosure provides intact bacterially derived minicells containing 40-50 nucleotides long double stranded RNA as nucleic acids adjuvants or plasmids encoding said nucleic acids adjuvants that can produce an interferon immune response from target cells. This disclosure further provides methods that employ minicells to deliver said nucleic acids adjuvants for use in the treatment of cancer or an infection in humans and non-human subjects.
Resumen de: WO2026064724A1
The present disclosure provides genetically modified Salmonella (GMS) strains with enhanced self-destructing and tumor-navigating activity.
Resumen de: US20260078140A1
Provided herein are compositions of trehalose phospholipids and uses thereof, e.g., compounds and compositions comprising 6,6′-diphosphatidyltrehalose (diPT) and analogs thereof with modifications of the diPT chemical scaffold, that bind and agonize Mincle, and the use thereof as adjuvants.
Resumen de: US20260079158A1
Disclosed are assays, reagents, and methods for ultrasensitive detection of target molecules. The assay comprises fusion proteins including binding moieties, such as antibodies, nanobodies (VHH/VNAR), or aptamers, linked to nonfunctional fragments of a protein. In the presence of a target molecule, the binding moieties recognize distinct target regions and bring the protein fragments into close proximity, reconstituting a functional protein that generates a detectable signal. Linkers connecting the fusion components may be flexible peptides or polypeptides that spontaneously form dimers, trimers, or tetramers, thereby providing multivalent fusion proteins with enhanced sensitivity. The reconstituted protein may produce luminescent, fluorescent, colorimetric, or spectroscopic signals detectable by microplate readers, handheld luminometers, or lateral flow devices. The invention encompasses solid-phase, homogeneous, and lateral flow assay formats for detecting viruses, bacteria, proteins, peptides, or small molecules, including GLRaV-3, SARS-CoV-2, PSA, and E. coli. The disclosed assays exhibit improved specificity, reduced background, and enhanced signal-to-noise ratios.
Resumen de: WO2024192346A1
Technologies for providing immunogenic compositions (e.g., vaccines) and methods of inducing immune responses in subjects in need thereof.
Resumen de: AU2024219856A1
- 41 The invention relates to methods of treating or preventing a disease or condition caused by or associated with a gram-negative bacterial infection in a subject in need thereof and compositions for use in such methods. More particularly, the present invention relates to agents and compositions, including concanavalin A, lactoferrin, colostrum and Ig from colostrum for use in the treatment or prevention of a disease or condition caused by or associated with a gram-negative bacterial infection and methods of using such agents and compositions.
Resumen de: EP4512482A2
The invention relates to an enriched population of modified lipopolysaccharide (LPS) molecular species being:- devoid of phosphate group at position C1 of the reducing end of their lipid A domain; and- substituted at position C6' of the non-reducing end of their lipid A domain by a hydrophilic moiety, with the proviso that said hydrophilic moiety is not a hydroxyl group.It also relates to compositions comprising the enriched population of modified LPS; and uses of naturally-occurring LPS molecular species and/or enriched population of modified LPS molecular species for treating and/or preventing cancer, inflammatory diseases or infectious diseases, and for stimulating an immune response or vaccinating a subject.
Resumen de: WO2026054672A1
The invention relates to the field of health care, and more particularly to the prevention of infections that cause pneumonia and other illnesses using an immunogenic protein containing fragments of the proteins FliC, PspA, OmpA and PE, connected by rigid linkers, wherein: - the FliC protein fragment contains SEQ ID NOs: 2 and 3 connected to one another by a flexible linker; - the PspA protein fragment contains SEQ ID NO: 4; the OmpA protein fragment contains SEQ ID NOs: 5-8 connected to one another by flexible linkers; - the PE fragment contains SEQ ID NO: 9. Also proposed are a host cell and a method for producing the protein. The immunogenic protein is suitable for use as a broad-spectrum polyvalent vaccine and exhibits a marked protective effect against Streptococcus pneumoniae, Haemophilus influenzae and Klebsiella pneumoniae, as well as providing for production efficiency and safety.
Nº publicación: EP4705504A1 11/03/2026
Solicitante:
MICROSENSOR LABS LLC [US]
Microsensor Labs, LLC
Resumen de: WO2024227138A1
A system and method for detecting, enumerating, or extracting microorganisms in a sample is disclosed. Target microorganisms, such as Salmonella bacteria, may be of interest. Magnetic beads may be bound to the target microorganisms. After which, the bead-bound cells may be isolated. For example, a magnetic field may be applied in order to separate the target cells (with the magnetic beads attached thereto) and move then to a predetermined section of the well. Agar, or other immobilizing agent, may be added to the wells in order to immobilize the target cells. After which, the target cells are incubated and periodically analyzed to determine whether the target cells are growing, thereby indicating that the microorganisms are contained within the well.
BOPI
Sede Electrónica
